The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 11, 2011, Pages 1713-1720

  Carreras, Enric ^a   Díaz Beyá, Marina ^a   Rosiñol, Laura ^a   Martínez, Carmen ^a   Fernández Avilés, Francesc ^a   Rovira, Montserrat ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Allogeneic stem cell transplantation; Defibrotide; Early complication of SCT; Sinusoidal obstruction syndrome; Veno occlusive disease

Indexed keywords

DEFIBROTIDE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME; VEIN OCCLUSION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SPAIN; TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054847190     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.06.006     Document Type: Article

References (18)

1. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000, 64:281-291.
2. Wadleigh M., Ho V., Momtaz P., Richardson P. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol 2003, 10:451-462.
3. McDonald G.B., Sharma P., Matthews D.E., Shulman H.M., Thomas E.D. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984, 4:116-122.
4. Jones R.J., Lee K.S., Beschorner W.E., et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987, 44:778-783.
5. Coppell J.A., Richardson P.G., Soiffer R., et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010, 16:157-168.
6. McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993, 118:255-267.
7. Rozman C., Carreras E., Qian C., et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 1996, 17:75-80.
8. Carreras E., Bertz H., Arcese W., et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998, 92:3599-3604.
9. Carreras E., Grañena A., Navasa M., et al. Transjugular liver biopsy in BMT. Bone Marrow Transplant 1993, 11:21-26.
10. Carreras E., Grañena A., Navasa M., et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol 1993, 66:77-80.
11. Nicolau C., Brú C., Carreras E., et al. Sonographic diagnosis and hemodynamic correlation in veno-occlusive disease of the liver. J Ultrasound Med 1993, 12:437-440.
12. Carreras E., Rosiñol L., Terol M.J., et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007, 13:1448-1454.
13. Palomo M., Diaz-Ricart M., Carbo C., et al. The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. Biol Blood Marrow Transplant 2009, 15:537-546.
14. Palomo M., Diaz-Ricart M., Carbo C., et al. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 2010, 16:985-993.
15. Ramasamy K., Lim Z.Y., Pagliuca A., et al. Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2006, 38:823-824.
16. Corbaciogly S., Cesaro S., Fareci M., et al. Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicentre study. Bone Marrow Transplant 2010, 45(Suppl 2):S1.
17. Palomo M., Diaz-Ricart M., Rovira M., Escolar G., Carreras E. Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:497-506.
18. Richardson P.G., Soiffer R.J., Antin J.H., et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010, 16:1005-1017.